Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

takeda manufacturing austria ag. - factor ix de coagulaciÓn humana - factor ix de coagulaciÓn humana....600ui / agua esterilizada para inyectables....5ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing austria ag, austria - human coagulation factor viii - powder and solvent for solution for injection - 500 iu,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing austria ag, austria - human coagulation factor viii - powder and solvent for solution for injection - 250 iu,

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

takeda manufacturing austria ag, austria - human coagulation factor viii - powder and solvent for solution for injection - 1000 iu,

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 3.29 mg (equivalent: ixazomib, qty 2.3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 4.3 mg (equivalent: ixazomib, qty 3 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide black; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 5.7 mg (equivalent: ixazomib, qty 4 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Israel - English - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 30 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Israel - English - Ministry of Health

takeda israel ltd - brigatinib - film coated tablets - brigatinib 90 mg - brigatinib - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Israel - English - Ministry of Health

takeda israel ltd - darvadstrocel - suspension for injection - darvadstrocel 5000000 cells/ml - darvadstrocel - alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. alofisel should be used only after conditioning of the fistulas.